TG Therapeutics, Inc. · TGTX · FY2025 Q2 · Calendar Q3 2025

BRIUMVI growth and raised outlook offset a quarterly consensus miss

The supplied analysis supports a growth case centered on BRIUMVI adoption, persistence, and a higher full-year U.S. sales outlook. The case is qualified by Q2 EPS and revenue misses, competitive and payer pressures, and limited near-term visibility without specific Q3 guidance.

Why did TGTX fall 18.0% after missing EPS estimates in FY2025 Q2?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNASDAQHealthcare $9.76B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.17 Consensus $0.32
EPS surprise -46.9% Reported versus consensus
Reported revenue $141.1M Consensus $146.3M
Revenue surprise -3.5% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move -18.0% Event window
SPY move +1.5% Same window
Abnormal move -19.5% Stock minus SPY
Volume 7.0× Versus trailing sessions
Subsequent drift +3.5% Up to 20 sessions
TGTXSPY benchmark

Ask FN2 about TGTX FY2025 Q2

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Management reported BRIUMVI Q2 net sales of $139 million, up 91% year over year, and raised full-year U.S. BRIUMVI revenue guidance to $570–$575 million. The previous quarter's analysis cited $119.7 million in Q1 U.S. sales and $560 million in full-year 2025 revenue guidance; the current quarter also adds progress on subcutaneous BRIUMVI Phase III enrollment and azer-cel dosing in progressive MS.

Guidance delta

Management raised full-year U.S. BRIUMVI revenue guidance to $570–$575 million. The supplied analysis notes no specific Q3 guidance.

Key takeaways

  • BRIUMVI sales and the raised full-year outlook indicate continued commercial momentum in management's account.
  • The supplied scorecard shows Q2 EPS of $0.17 versus $0.32 estimated and revenue of $141.148 million versus $146.274 million estimated.
  • Management cited new prescribers, patient enrollment, repeat prescribing, and persistence as demand indicators.
  • Subcutaneous BRIUMVI and azer-cel represent development priorities, not current commercial contributors in the supplied analysis.

Management priorities

  • Complete enrollment for the subcutaneous BRIUMVI Phase III program, with a BLA filing planned for 2027 and launch targeted for 2028.
  • Continue national television and digital marketing campaigns.
  • Advance azer-cel CAR-T development and explore additional indications.

Follow TGTX with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
TGTX EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q2 '24 estimate $-0.05 Q2 '24 actual $0.04, beat Q3 '24 estimate $0.03 Q3 '24 actual $0.02, match Q2 '25 estimate $0.32 Q2 '25 actual $0.17, miss Q3 '25 estimate $0.24 Q3 '25 actual $2.43, beat Q4 '25 estimate $0.35 Q4 '25 actual $0.14, miss Q1 '26 estimate $0.23 Q1 '26 actual $0.14, miss Q2 '26 estimate $0.31 Q2 '26 actual $0.05, miss Q3 '26 estimate $0.36 Q3 '26 actual $0.35, match Q4 '26 estimate $0.52 Q1 '27 estimate $0.64 Q2 '27 estimate $0.71 Q3 '27 estimate $0.75
Show 2 more >

Analyst Consensus ?

ConsensusBuy13 ratings
Bullish1184.6%
Neutral17.7%
Bearish17.7%

Analyst 52W Price Targets

$63.34Current
$11.5Low
$41Average
$83High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Evercore ISI Group Outperform OutperformMaintainNov 10, 2026
HC Wainwright & Co. Buy BuyMaintainSep 1, 2026
JP Morgan Overweight OverweightMaintainAug 7, 2026
B. Riley Securities Buy BuyMaintainJul 27, 2026
B of A Securities Underperform UnderperformMaintainJul 7, 2026
Show 8 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $63.34. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
H.C. WainwrightEmily Bodnar$78$46.17 +23.1%Aug 4, 2026
JefferiesAnalyst unavailable$83$54.4 +31.0%Jun 22, 2026
H.C. WainwrightAnalyst unavailable$70$39.75 +10.5%May 6, 2026
Goldman SachsAnalyst unavailable$39$29.54 -38.4%Jan 15, 2026
H.C. WainwrightEmily Bodnar$60$36.7 -5.3%Oct 6, 2025
See 8 more

Track every rating change on TGTX the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma.…

Historical context

All TGTX earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the TGTX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-11-13T22:50:47.022910+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-13T22:50:47.019722+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-13. For educational purposes only; not investment advice.